COVID-19 Treatments: Controversies and Conflicts

This chapter explores the contentious debate over COVID-19 treatment options, particularly focusing on monoclonal antibodies and ivermectin. The discussion highlights concerns over the Biden administration's alleged obstruction of treatment distribution in favor of vaccination, as well as the financial disparities affecting research on generic drugs. Ultimately, the chapter underscores the complexities of healthcare decision-making amid the pandemic and the need for more comprehensive data to better inform public health strategies.